# Spatially Resolved, Multi-Omics Analyses of Immune Infiltrates in GBM Microenvironment

> **NIH NIH R43** · ATLASXOMICS INC. · 2022 · $251,087

## Abstract

Abstract: In this SBIR grant, AtlasXomics Inc. proposes to develop a novel spatial
immunophenotyping device that maps immune infiltrates in the mouse brain tumor
microenvironment (TME) by spatially co-profiling ~20 immune surface protein biomarkers and the
whole transcriptome (WT) with cellular resolution. In collaboration with researchers at the National
Cancer Institute (NCI), we will demonstrate the ability of this device to richly characterize their
potentially transformative immunotherapy for glioblastoma (GBM). Company founder Professor
Rong Fan developed the basis for the device, Deterministic Barcoding in Tissue for spatial omics
sequencing (DBiT-seq), to enable cellular-resolution mapping of the whole transcriptome, high-
plex proteome, and genome-wide epigenome.
AtlasXomics proposes in Phase I to develop a next-generation immunophenotyping device to
map immune infiltrates in the TME by combining same-section WT and proteomic data. DBiT-
seq’s unique microfluidics approach enables co-profiling of WT and proteins. The next-generation
immunophenotyping device will build on the proven ability of protein biomarkers to characterize
immune phenotypes by incorporating both cellular-resolution mapping and the discovery potential
imparted by same-section WT coverage.
Aim 1: Develop a spatial multi-omics immunophenotyping device (proteome and whole
transcriptome) to identify and map immune infiltrates in the GBM microenvironment.
Aim 2: Demonstrate application of the next generation immunophenotyping device by
mapping and identifying immune infiltrates in NCI’s GBM mouse model.
After Phase I, we will have demonstrated that the next generation immunophenotyping assay
achieves cellular resolution co-profiling of whole transcriptome and a tailored protein panel,
thereby enabling mapping and characterization of immune infiltrates in the TME. This device will
help improve understanding of the mechanisms underlying various immunotherapy treatments.
Upon demonstrating the value of the novel spatial immunophenotyping device to NCI’s vaccine
development program, AtlasXomics will scale the product's throughput, robustness through
semi-automation and advanced chip designs. An optimized mouse brain-specific multi-omics
immunophenotyping device would enable cancer researchers to better understand how immune
infiltration underpins cancer immunotherapy. A next generation immunophenotyping device
combining cellular resolution proteomics and WT will become a standard tool to promote solid
tumor cancer immunotherapy treatment development.

## Key facts

- **NIH application ID:** 10483889
- **Project number:** 1R43CA272107-01
- **Recipient organization:** ATLASXOMICS INC.
- **Principal Investigator:** Jennifer Mary Garbarino
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $251,087
- **Award type:** 1
- **Project period:** 2022-09-16 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10483889

## Citation

> US National Institutes of Health, RePORTER application 10483889, Spatially Resolved, Multi-Omics Analyses of Immune Infiltrates in GBM Microenvironment (1R43CA272107-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10483889. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*